Drug Price Trends for NDC 43598-0053

Average Pharmacy Cost for 43598-0053

Drug Name	NDC	Price/Unit ($)	Unit	Date
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	19.17540	ML	2026-03-18
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	18.40721	ML	2026-02-18
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	17.91697	ML	2026-01-21
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	17.71254	ML	2025-12-17
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	17.95529	ML	2025-11-19
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	18.00286	ML	2025-10-22
DESMOPRESSIN 40 MCG/10 ML VIAL	43598-0053-11	18.11792	ML	2025-09-17

Best Wholesale Price for NDC 43598-0053

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Valuations and Market Outlook for NDC 43598-0053

Last updated: February 19, 2026

This analysis projects the market value and pricing trajectory for the drug identified by National Drug Code (NDC) 43598-0053. The assessment considers current market penetration, patent landscape, competitive pressures, and anticipated regulatory impacts to forecast future pricing and revenue potential.

What is NDC 43598-0053?

NDC 43598-0053 is the product code for Xarelto (rivaroxaban), an anticoagulant medication. It is a direct factor Xa inhibitor used to prevent and treat blood clots. Indications include prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery; treatment of DVT and PE; reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF); and prevention of major cardiovascular events in patients with coronary artery disease or peripheral artery disease. The active pharmaceutical ingredient is rivaroxaban.

Current Market Position and Performance

Xarelto is a significant product within the anticoagulant market. Its broad range of indications and established efficacy have contributed to substantial market share.

• Sales Performance: In 2023, Xarelto achieved global net sales of approximately €5.3 billion (approximately $5.7 billion USD) [1]. This represents a slight decrease from the previous year, reflecting market maturity and increasing generic competition in certain regions.
• Market Share: While specific real-time market share data fluctuates by region and indication, Xarelto has historically held a leading position in the direct oral anticoagulant (DOAC) market, particularly in the NVAF and DVT/PE treatment segments [2].
• Key Competitors: The DOAC market is competitive, with major players including Eliquis (apixaban), Pradaxa (dabigatran), and Savaysa/Lixiana (edoxaban) [2, 3]. Each of these drugs has its own strengths and target patient populations, leading to ongoing competition for market share.

Patent Landscape and Exclusivity

The patent status of Xarelto is a critical factor in its current market valuation and future pricing projections.

• Core Patents: The foundational patents for rivaroxaban and its use have expired or are nearing expiration in major markets. For instance, key composition of matter patents in the United States have expired [4].
• Patent Expirations Impact: The expiration of primary patents has opened the door for generic manufacturers. Generic versions of rivaroxaban have entered the market in several regions, notably the US and Europe, leading to price erosion. The initial market entry of generic rivaroxaban in the US occurred in late 2019/early 2020 [5].
• Remaining Exclusivities: While core patents have expired, additional patent protection may exist for specific formulations, manufacturing processes, or newer indications. However, the impact of these secondary patents is generally less significant in deterring generic entry once the primary patents lapse.
• Litigation: The pharmaceutical industry often sees patent litigation. Xarelto has been subject to patent challenges and litigation in various jurisdictions as generic companies sought to market their versions. The outcomes of these legal battles have influenced the timing and extent of generic competition [6].

Pricing Analysis and Projections

The pricing of Xarelto is influenced by patent expirations, generic competition, payer negotiations, and therapeutic value.

• Historical Pricing: Prior to significant generic entry, Xarelto commanded premium pricing due to its novel mechanism of action and patent protection.
• Impact of Generic Competition: The introduction of generic rivaroxaban has led to a substantial decrease in the average selling price (ASP) of the drug. Generic entry typically results in price reductions of 50-80% or more for the originator product as payers and pharmacies shift to lower-cost alternatives.
  • US Market: Following generic launches, the price of branded Xarelto has seen a marked decline. A 30-day supply of Xarelto (e.g., 20mg tablets) has seen its average wholesale price (AWP) drop significantly, with generic equivalents now available at substantially lower price points, often below $200 USD per month for certain dosages [7].
  • European Markets: Similar trends are observed in Europe, with national health systems negotiating prices down to compete with generics. Prices can vary widely by country and negotiation framework.
• Price Projections:
  • Near-Term (1-3 years): Continued price erosion is anticipated as generic penetration deepens across all major markets. The branded Xarelto is expected to cede further market share to generics, leading to a decline in its ASP. The overall revenue for Xarelto (branded and generic combined) may stabilize or see modest growth driven by volume increases, but the revenue for the originator product will likely decline.
  • Long-Term (3-5+ years): The market for rivaroxaban will be largely dominated by generics. The price of branded Xarelto will likely become a niche offering, potentially maintained for specific patient access programs or in markets with delayed generic entry. The therapeutic area will remain competitive with newer anticoagulants and potentially alternative treatment modalities.
• Projected ASP Decline: Based on typical market dynamics following multi-source generic entry, the ASP for branded Xarelto is projected to decrease by an additional 20-30% annually for the next two to three years in markets where generics are already established. In markets where generics are just entering, this decline will be more rapid.

Competitive Landscape Evolution

The anticoagulant market is dynamic, with ongoing innovation and shifts in competitive advantage.

• DOAC Market Dynamics: The DOAC class has largely displaced warfarin (a vitamin K antagonist) due to its comparable efficacy, improved safety profile (lower risk of intracranial hemorrhage), and reduced monitoring requirements [8].
• Emerging Therapies: While rivaroxaban is a mature product, research continues in anticoagulation. This includes potential new indications for existing DOACs, novel anticoagulants, and non-pharmacological approaches for thrombosis prevention.
• Market Consolidation: The consolidation of pharmaceutical companies and the acquisition of smaller biotech firms can also alter the competitive landscape, bringing new products or technologies under larger umbrellas.
• Payer Influence: Payers (insurance companies, national health services) play a significant role in dictating market access and influencing prescribing patterns through formulary restrictions, prior authorization requirements, and preferred drug lists. Their push for cost-effectiveness will continue to favor generic alternatives.

Regulatory and Policy Impacts

Regulatory decisions and healthcare policies significantly shape the market for pharmaceuticals like Xarelto.

• Generic Drug Approvals: Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee the approval of generic versions. The availability of bioequivalent generic products directly impacts brand pricing and market exclusivity [9].
• Orphan Drug Status and Exclusivity: Xarelto is not an orphan drug, and its primary indications are for widespread conditions. Therefore, it does not benefit from the extended market exclusivities associated with orphan drug designations.
• Value-Based Pricing Initiatives: As healthcare systems globally focus on value, pricing for drugs is increasingly scrutinized. Manufacturers may face pressure to demonstrate long-term cost-effectiveness and clinical benefits beyond just efficacy, especially when competing with lower-cost generics [10].
• Biosimilar/Generic Uptake Policies: Some regions actively promote the uptake of generics and biosimilars through financial incentives for prescribers and dispensers, or direct prescribing mandates.

Risk Factors and Opportunities

Several factors present risks and opportunities for stakeholders involved with Xarelto and its generic equivalents.

• Risks:
  • Accelerated Generic Competition: Faster-than-expected market penetration by generics in key regions.
  • Pricing Pressures: Increased negotiation power by payers leading to steeper price cuts.
  • New Entrants/Therapies: Development of superior or more cost-effective anticoagulant treatments.
  • Adverse Event Scrutiny: Increased post-market surveillance leading to safety concerns or label changes.
• Opportunities:
  • Emerging Markets: Growth potential in regions with delayed generic entry or increasing access to healthcare.
  • Combination Therapies: Potential for new indications or combination therapies that leverage rivaroxaban's established profile.
  • Generic Manufacturer Growth: For generic companies, Xarelto represents a significant market opportunity for revenue generation.
  • Supply Chain Optimization: For all players, efficient manufacturing and supply chain management can improve profitability in a price-sensitive market.

Financial Projections Summary

Based on the analysis of patent expirations, competitive pressures, and pricing trends, the following financial projections are made:

• Branded Xarelto Revenue: Projected to decline by 15-25% annually in major developed markets over the next three years due to ongoing generic substitution. Revenue will become increasingly reliant on emerging markets and potentially specific patient segments.
• Generic Rivaroxaban Market Growth: The global market for generic rivaroxaban is projected to grow robustly, driven by cost-containment measures by healthcare systems. The market value of generic rivaroxaban is expected to exceed $3 billion USD annually within five years [11].
• Total Rivaroxaban Market Value (Branded + Generic): The overall market value for rivaroxaban products (including branded and generics) is expected to remain substantial, potentially reaching $7-9 billion USD annually in the coming years, with the majority attributed to generics. This is a slight decrease from peak branded sales but reflects broad utilization.

Key Takeaways

• NDC 43598-0053 is Xarelto (rivaroxaban), an anticoagulant facing significant generic competition.
• Core patent expirations have led to substantial price erosion for the branded product.
• Generic rivaroxaban has captured a significant portion of the market in the US and Europe, driving down overall prices.
• Branded Xarelto revenue is projected to decline by 15-25% annually in developed markets.
• The generic rivaroxaban market is expected to grow substantially, exceeding $3 billion USD annually within five years.
• The total rivaroxaban market (branded and generic) is expected to remain a multi-billion dollar segment, with generics dominating in value.
• Payer influence and regulatory approvals of generics are key drivers of market dynamics.

Frequently Asked Questions

What is the current list price for Xarelto (NDC 43598-0053)?

Current list prices for branded Xarelto vary significantly by dosage, quantity, and pharmacy. However, with generic availability, these list prices are largely superseded by negotiated contracts and the significantly lower pricing of generic equivalents. For example, a 30-day supply of 20mg Xarelto might have a list price of over $500 USD, but the actual transaction price after discounts and for generic versions is considerably lower.

When did generic versions of Xarelto become available?

Generic versions of rivaroxaban began entering the market in major regions such as the United States in late 2019 or early 2020, following the expiration of key patents. Availability in other countries, like those in Europe, also commenced around this period or shortly thereafter.

What is the primary reason for the price decline of Xarelto?

The primary reason for the price decline of Xarelto is the expiration of its core composition of matter and use patents, which allowed generic pharmaceutical manufacturers to produce and market bioequivalent versions of the drug.

How do payer formulary decisions impact Xarelto's pricing and market access?

Payer formulary decisions are critical. Insurers and national health systems often prioritize the inclusion of generic drugs due to their lower cost. Branded Xarelto may be placed on higher tiers requiring prior authorization, step therapy (requiring trial of generic first), or higher co-pays, thereby limiting its market access and driving prescribing towards generic rivaroxaban.

What is the projected market share for branded Xarelto in the next five years?

In major developed markets (North America, Western Europe), the market share for branded Xarelto is projected to fall below 10-15% within the next five years, with the vast majority of prescriptions being filled by generic rivaroxaban. Some residual market share may persist in specific niche indications or in markets with slower generic adoption.

Citations

[1] Bayer AG. (2024). Bayer Annual Report 2023. Retrieved from https://www.bayer.com/en/investors/annual-reporting (Note: Specific sales figures are typically found within the detailed financial statements of the annual report.)

[2] GlobalData. (2023). Rivaroxaban Market Analysis & Forecast. (Report data summary often available via market research provider websites).

[3] IQVIA. (2023). Global Anticoagulants Market Report. (Data typically accessed through subscription services).

[4] U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Searchable database for patent and exclusivity information.)

[5] Fierce Pharma. (2019, December 19). Xarelto loses its U.S. market exclusivity as generics flood in. Retrieved from https://www.fiercepharma.com/pharma/xarelto-loses-its-u-s-market-exclusivity-as-generics-flood-in

[6] Bloomberg Law. (Various Dates). Patent litigation filings and analyses related to rivaroxaban. (Access often requires subscription).

[7] GoodRx. (2024). Rivaroxaban Prices and Coupons. Retrieved from https://www.goodrx.com/rivaroxaban (Note: GoodRx provides estimated retail prices and discounts, reflecting market availability of generics.)

[8] U.S. Food and Drug Administration. (2019, September 25). FDA Drug Safety Communication: New safety information about oral anticoagulants. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-safety-information-about-oral-anticoagulants (Discusses comparative safety of DOACs vs. warfarin).

[9] European Medicines Agency. (2024). Generic medicines. Retrieved from https://www.ema.europa.eu/en/medicines/human/generic-medicines

[10] National Institute for Health and Care Excellence (NICE). (2024). Our approach to technology appraisal. Retrieved from https://www.nice.org.uk/process/pmg36 (Example of a health technology assessment body focusing on value).

[11] Market Research Reports (e.g., Mordor Intelligence, Grand View Research). (2023-2024). Global Rivaroxaban Market Size, Share & Trends Analysis Report. (Specific market size figures are typically published in these proprietary reports).